A Study of PF-07275315 and PF-07264660 for Moderate to Severe Atopic Dermatitis
This study is looking into the safety and effects of two potential new medicines, PF-07275315 and PF-07264660, for people with moderate to severe atopic dermatitis (AD). AD is a long-lasting, itchy red rash. You might be able to join if you are 18 or older, have had AD for at least six months, and your current skin-applied treatments aren't working well. Participants will receive either PF-07275315, PF-07264660, or a placebo (an inactive substance) through injections under the skin. The study aims to see if these medicines can significantly improve your AD symptoms by Week 16.
- Study design
- This is an interventional study with a planned enrollment of 340 participants. Participants will receive either PF-07275315, PF-07264660, or a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at Week 16, indicating participants are followed at least until then.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
At a glance
Conditions
Where it's being run
98 sites across 54 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.Week 16
EASI75 (≥75% improvement from baseline) at Week 16